Duobrii vs. Taltz

• Are Duobrii and Taltz the Same Thing?
• What Are Possible Side Effects of Duobrii?
• What Are Possible Side Effects of Taltz?
• What Is Duobrii?
• What Is Taltz?
• What Drugs Interact with Duobrii?
• What Drugs Interact with Taltz?
• How Should Duobrii Be Taken?
• How Should Taltz Be Taken?

Duobrii (halobetasol propionate and tazarotene) Lotion and Taltz (ixekizumab) injection are used to treat plaque psoriasis in adults.

Duobrii Lotion is a topical (for the skin) treatment and Taltz is given as a subcutaneous injection.

Duobrii and Taltz belong to different drug classes. Duobrii is a combination of a corticosteroid and a retinoid and Taltz is a humanized interleukin-17A antagonist.

Side effects of Duobrii that are different from Taltz include contact dermatitis, application site pain, infected hair follicles, thinning skin, skin abrasions, rash, stretch marks, and skin peeling.

Side effects of Taltz that are different from Duobrii include injection site reactions (redness, pain), upper respiratory tract infections (runny or stuffy nose, rhinovirus infections), nausea, and fungal infections (ringworm, athlete's foot and jock itch).

Duobrii may interact with corticosteroids taken by mouth or injection and other products used on your skin that contain corticosteroids.

Taltz may interact with "live" vaccines, warfarin, and cyclosporine.

Common side effects of Duobrii include:

• contact dermatitis,
• application site pain,
• infected hair follicles,
• thinning skin,
• skin abrasions,
• rash,
• stretch marks, and
• skin peeling

Common side effects of Taltz include:

• contact dermatitis,
• application site pain,
• infected hair follicles,
• thinning skin,
• skin abrasions,
• rash,
• stretch marks, and
• skin peeling

Duobrii (halobetasol propionate and tazarotene) Lotion is a combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults.

Taltz (ixekizumab) injection is a humanized interleukin-17A antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Duobrii Lotion may interact with corticosteroids taken by mouth or injection, or other products used on your skin that contain corticosteroids. Tell your doctor all medications and supplements you use. Duobrii Lotion is not recommended for use during pregnancy; it may harm a fetus. A negative result for pregnancy should be obtained within 2 weeks prior to Duobrii Lotion therapy, which should begin during menstruation. Females of reproductive potential are advised to use effective contraception during treatment with Duobrii Lotion. It is unknown if Duobrii passes into breast milk.

Taltz may interact with "live" vaccines, warfarin, and cyclosporine. Tell your doctor all medications and supplements you use and all vaccines you recently received.

Apply a thin layer dose of Duobrii Lotion to the affected areas once daily.

The recommended dose of Taltz is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.